1. | Limitations of current animal models to predict efficacy of cancer immunotherapy strategies in humans |
2. | Prolonged time to obtain approval to initiate clinical trials |
3. | Complexity of cancer, tumor heterogeneity and immune escape |
4. | Limited availability of reagents for combination immunotherapy studies |
5. | Limited funds available to translate science into patients |
6. | Lack of definitive biomarker(s) for assessment of clinical efficacy of cancer immunotherapies |
7. | Conventional clinical response criteria do not take into consideration differences between response patterns to cytotoxic agents and immunotherapies |
8. | Paucity of teams of scientists and clinicians dedicated to translational research in cancer immunotherapy |
9. | Insufficient exchange of information critical to advancing the field |